A trial of VAL 083 in patients with non-small cell lung cancer
Phase of Trial: Phase IV
Latest Information Update: 02 Sep 2015
Price : $35 *
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Del Mar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical
- 02 Sep 2015 According to a DelMar pharmaceuticals media release, details of this trial will be presented at the 16th World Conference on Lung Cancer.
- 15 Jun 2015 This study will be covered in a presentation by DelMar Pharmaceuticals at The World NSCLC Summit, according to a company media release.
- 09 Oct 2014 Following successful in vivo studies of VAL 083 in models of NSCLC, DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals are expecting to conduct a clinical trial of VAL 083 in patients in China, according to a media release.